全文获取类型
收费全文 | 36084篇 |
免费 | 3074篇 |
国内免费 | 127篇 |
专业分类
耳鼻咽喉 | 363篇 |
儿科学 | 862篇 |
妇产科学 | 569篇 |
基础医学 | 4682篇 |
口腔科学 | 1049篇 |
临床医学 | 4214篇 |
内科学 | 7892篇 |
皮肤病学 | 1033篇 |
神经病学 | 2975篇 |
特种医学 | 1221篇 |
外科学 | 4449篇 |
综合类 | 510篇 |
现状与发展 | 1篇 |
一般理论 | 27篇 |
预防医学 | 4005篇 |
眼科学 | 569篇 |
药学 | 2752篇 |
中国医学 | 73篇 |
肿瘤学 | 2039篇 |
出版年
2023年 | 236篇 |
2022年 | 415篇 |
2021年 | 864篇 |
2020年 | 462篇 |
2019年 | 770篇 |
2018年 | 887篇 |
2017年 | 583篇 |
2016年 | 632篇 |
2015年 | 752篇 |
2014年 | 1042篇 |
2013年 | 1454篇 |
2012年 | 2103篇 |
2011年 | 2057篇 |
2010年 | 1164篇 |
2009年 | 1009篇 |
2008年 | 1743篇 |
2007年 | 1739篇 |
2006年 | 1671篇 |
2005年 | 1729篇 |
2004年 | 1559篇 |
2003年 | 1472篇 |
2002年 | 1421篇 |
2001年 | 1041篇 |
2000年 | 1029篇 |
1999年 | 915篇 |
1998年 | 370篇 |
1997年 | 312篇 |
1996年 | 292篇 |
1995年 | 298篇 |
1994年 | 227篇 |
1993年 | 243篇 |
1992年 | 633篇 |
1991年 | 650篇 |
1990年 | 597篇 |
1989年 | 522篇 |
1988年 | 496篇 |
1987年 | 486篇 |
1986年 | 481篇 |
1985年 | 477篇 |
1984年 | 353篇 |
1983年 | 306篇 |
1982年 | 224篇 |
1981年 | 213篇 |
1979年 | 330篇 |
1978年 | 245篇 |
1977年 | 207篇 |
1974年 | 219篇 |
1973年 | 206篇 |
1971年 | 194篇 |
1970年 | 172篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
42.
43.
44.
45.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
46.
Alfentanil is an opioid that has been used both as a sole anesthetic and in conjunction with other inhalation anesthetics. However, its effects on myocardial performance and regional blood flow are not clearly known. Using sonomicrometry and radioactive microsphere techniques, we examined the hemodynamic responses to alfentanil when given as a loading dose (45 micrograms/kg) followed by continuous infusion (3 micrograms X kg-1 X min-1) in dogs anesthetized with halothane. Similar plasma levels of alfentanil were observed after the loading and infusion doses, and both techniques of administration produced a significant reduction in arterial pressure without change in global or regional function of the left ventricle. Although cardiac output and left ventricular end-diastolic pressure remained unchanged, heart rate and systemic vascular resistance decreased significantly after the loading dose and recovered slightly when alfentanil was infused continuously. Despite the systemic hypotension, alfentanil did not alter perfusion to the heart, brain, muscle, and skin; however, blood flow to the renal cortex and the arterial supply to the liver decreased by 25 and 60%, respectively. Reduction in blood flow to the kidneys and the liver suggests that alfentanil should be used with caution when normal function of these organs is in question. 相似文献
47.
48.
Aneurisma de aorta abdominal infrarrenal en asociación con riñón en herradura: aportación de un caso
Nerea Senarriaga Ruiz de la Illa Reyes Vega Manrique Isabel Lacasa Viscasillas Iñaki Iriarte Soldevilla Miguel Unda Urzaiz 《Actas urologicas espa?olas》2009,33(10):1141-1144
We review the association between surgically resolvable aortic disease and horseshoe kidney with a discussion of diagnostic problems and therapeutic options.Male patient 81 years of age with horseshoe kidney and an abdominal aortic aneurysm that was discovered by chance in an abdominal ultrasound during a check-up for his prostate condition.A retroperitoneal approach was used in order to resect the aneurysm and perform an aorto-aortic bypass with no complications occurring. Two years after the diagnosis, the patient is still asymptomatic from a vascular point of view.The co-presence of horseshoe kidney and aortic disease needing surgical correction is infrequent, but it significantly increases the technical complexity of aortic reconstruction. A literature review is included. 相似文献
49.
Marta Méndez-López Magdalena Méndez Fernando Sánchez-Patán Isabel Casado Maria-Angeles Aller Laudino López Maria-Teresa Corcuera Maria-Jose Alonso Maria-Paz Nava Jaime Arias Jorge-Luis Arias 《Journal of gastrointestinal surgery》2007,11(2):187-194
To obtain a new model of chronic portal hypertension in the rat, two classical methods to produce portal hypertension, partial portal vein ligation and the oral administration of thioacetamide (TAA), have been combined. Male Wistar rats were divided into four groups: 1 (control; n?=?10), 2 [triple partial portal vein ligation (TPVL); n?=?9], 3 (TAA; n?=?11), and 4 (TPVL plus TAA; n?=?9). After 3 months, portal pressure, types of portosystemic collateral circulation, laboratory hepatic function tests (aspartate aminotransferase, alanine aminotransferase, bilirubin, alkaline phosphatase, and gamma-glutamyl transpeptidase) and liver histology were studied. The animals belonging to group 2 (TPVL) developed extrahepatic portosystemic collateral circulation, associated with mesenteric venous vasculopathy without hepatic destructurization or portal hypertension. Animals from group 3 (TAA) developed cirrhosis and portal hypertension but not extrahepatic portosystemic collateral circulation, or mesenteric venous vasculopathy. Finally, the animals from group 4 (TPVL?+?TAA) developed cirrhosis, portal hypertension, portosystemic collateral circulation, and mesenteric venous vasculopathy. The association of TPVL and TAA can be used to obtain a model of chronic portal hypertension in the rat that includes all the alterations that patients with hepatic cirrhosis usually have. This could, therefore, prove to be a useful tool to study the pathophysiological mechanisms involved in these alterations. 相似文献
50.
Usher syndrome: clinical findings and gene localization studies 总被引:3,自引:0,他引:3
William J. Kimberling Sandra L. H. Davenport Ira Priluck Valorie White Karen Biscone-Halterman Patrick E. Brookhouser Claes G. Mller Gunnar Lund Timothy J. Grissom Michael D. Weston 《The Laryngoscope》1989,99(1):66-72
The issue of genetic heterogeneity is a critical problem in the localization of the gene(s) for Usher syndrome. Based on the data obtained on families studied to date, the differences between type I and type II Usher syndrome appear quite distinct with regard to auditory and vestibular function. Although the majority of families can be confidently diagnosed as typical type I or type II, clinical investigations revealed four families with findings that did not fit into either of the two more common subtypes. These findings emphasize the critical importance of an in-depth clinical analysis concomitant with the linkage investigation to assure accurate subtyping of Usher syndrome. Based on an analysis of only those families with definite type I or type II Usher syndrome, approximately 17% of the genome can be excluded as a potential site of the gene for type I, and 14% can be excluded as the site for the type II gene. This study will continue until the Usher gene(s) is successfully localized. 相似文献